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Tissue engineering is a rapidly growing ﬁ  eld that seeks to 
repair or regenerate injured or diseased tissues using 
combinations of cells, biomaterials, and biologically 
active molecules. With few exceptions, engineered 
tissues have been based on the use of autologous or 
allogeneic cells that have been removed from the body 
and then reintroduced following a variety of possible 
mani  pulations, such as cell expansion, exposure to 
growth factors, seeding in scaﬀ   olds, exposure to bio-
physical stimulation, or even genetic transfection.
Th   ese approaches have shown tremendous promise in 
the repair of many diﬀ  erent tissues and organs, such as 
skin, cartilage, blood vessels, trachea, bladder, or bone 
(for example, [1-4]). Despite many rapid advances in the 
ﬁ   eld, however, few tissue-engineered products are 
currently available in the clinical setting. One of the 
major hurdles in the commercialization of such 
approaches has been the complexity and, to a certain 
extent, the uncertainty of the regulatory pathway for 
ensur  ing the safety and eﬃ     cacy of products that can 
involve combinations of cells, biomaterials, and growth 
factors [5-7]. Speciﬁ  c to cartilage repair, few techniques 
have been able to restore the functional mechanical 
properties of native articular cartilage in the joint [8].
In their ground-breaking study, Lee et al. [9] show a 
proof-of-concept that an acellular ‘smart’ scaﬀ  old  can 
regenerate the articular surface of a rabbit synovial joint 
through induced homing of local cells using transforming 
growth factor (TGF)β3. To create the scaﬀ  old,  the 
morphology of the shoulder joint (proximal humerus) 
was recorded using a laser scanner, and an anatomically 
correct scaﬀ  old was created from poly(ε-caprolactone) 
and hydroxyapatite, in the shape of the joint surface. Th  e 
scaﬀ   old was infused with TGFβ3-adsorbed collagen 
hydrogel. Four months after surgery, the scaﬀ  olds 
contain  ing TGFβ3 were covered with hyaline cartilage 
with mechanical properties similar to those of native 
tissue. Importantly, the acellular scaﬀ   old had been 
repopulated by autologous cells that had then produced a 
hyaline-like cartilage layer. Th  e source of the cells that 
regenerated the joint surface, although not deﬁ  nitively 
identiﬁ  ed, appeared to be stem/progenitor cells in the 
synovium [10].
Th   is study provides some of the ﬁ  rst evidence that an 
acellular scaﬀ  old, loaded with the proper growth factor, 
can not only attract local cells to migrate into the scaﬀ  old, 
but also induce diﬀ  erentiation of those cells into a chon-
dro  genic phenotype. By removing the need for exogenous 
cell seeding, Lee and colleagues have circumvented many 
of the steps associated with cell-based therapies, includ-
ing cell isolation, seeding, and potential complications, 
such as disease transmission, immunogenicity, or tumori-
genesis. In this respect, an acellular approach to tissue 
repair is likely to encounter fewer regulatory hurdles 
compared to a cell-based therapy.
In addition to the proof-of-concept that a single growth 
factor can be used to induce repopulation of an acellular 
scaﬀ   old with local progenitor cells, this study also 
highlights the importance and challenges in developing 
bioartiﬁ  cial technologies that can be used to regenerate 
entire joint surfaces. With few exceptions (for example, 
[11-13]), most tissue engineering approaches for cartilage 
regeneration have focused on the repair of focal defects 
in the joint surface. While approaches such as autologous 
chondrocyte implantation continue to show promise [3], 
the frequency of such isolated cartilage defects is 
signiﬁ   cantly lower than the incidence of degenerative 
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hundreds of millions of adults worldwide at a tremendous 
economic burden. Present treatment options for osteo-
arthritis are limited, and surgical management generally 
involves joint replacement with a metal and polyethylene 
prosthesis. While joint replacement is a well-established 
procedure, its relatively short lifespan makes this 
treatment unacceptable for younger or more active 
indivi  duals, often requiring additional surgeries that 
involve progressively more complicated treatment with 
each joint replacement. Metal-on-metal joint prostheses 
showed early success as a novel means of joint re-
surfacing, but an increasing number of recent failures 
[14] has led to recalls of several such implants, further 
emphasizing the need for new technologies for treating 
degenerative joint disease.
Clearly, further study is needed to examine the 
feasibility of this technology in other joints, as well as its 
translation to the clinical setting. Nonetheless, the 
technique shown by Lee and colleagues provides a 
glimpse into the exciting possibility that tissue 
engineering may in fact provide a novel means for 
regenerating an entire joint surface, beyond a simple 
focal defect in the articular cartilage.
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